{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:22:17Z","timestamp":1786123337844,"version":"build-2736575974"},"reference-count":110,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1213\/ane.0b013e31820e7e4f","type":"journal-article","created":{"date-parts":[[2011,3,9]],"date-time":"2011-03-09T06:21:53Z","timestamp":1299651713000},"page":"777-799","source":"Crossref","is-referenced-by-count":14,"title":["Emergency Cardiac Surgery in Patients with Acute Coronary Syndromes"],"prefix":"10.1213","volume":"112","author":[{"given":"Charles","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brijen","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nauder","family":"Faraday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Yuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Rade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles W.","family":"Hogue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210902","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1001\/jama.293.23.2908","article-title":"Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials.","volume":"293","author":"Mehta","year":"2005","journal-title":"JAMA"},{"key":"R3-7-20210902","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.jacc.2005.06.083","article-title":"Emergency coronary artery bypass surgery for percutaneous coronary interventions: changes in the incidence, clinical characteristics, and indications from 1979 to 2003.","volume":"46","author":"Yang","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R4-7-20210902","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(94)91161-4","article-title":"Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients.","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"R6-7-20210902","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","article-title":"Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.","volume":"355","author":"Eikelboom","year":"2000","journal-title":"Lancet"},{"key":"R7-7-20210902","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jacc.2009.03.083","article-title":"Antithrombotics in acute coronary syndromes.","volume":"54","author":"Bonaca","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R9-7-20210902","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00019501-199606000-00003","article-title":"Biological rationale for the therapeutic role of specific antithrombins.","volume":"7","author":"Weitz","year":"1996","journal-title":"Coron Artery Dis"},{"key":"R11-7-20210902","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jtcvs.2009.04.052","article-title":"Antiplatelet agents used for early intervention in acute coronary syndrome: myocardial salvage versus bleeding complications.","volume":"138","author":"Aranki","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R13-7-20210902","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archsurg.133.4.442","article-title":"Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group.","volume":"133","author":"Dacey","year":"1998","journal-title":"Arch Surg"},{"key":"R14-7-20210902","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(03)12195-2","article-title":"Transfusion medicine: looking to the future.","volume":"361","author":"Goodnough","year":"2003","journal-title":"Lancet"},{"key":"R15-7-20210902","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.jvca.2004.11.002","article-title":"Preoperative use of enoxaparin increases the risk of postoperative bleeding and re-exploration in cardiac surgery patients.","volume":"19","author":"McDonald","year":"2005","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R16-7-20210902","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","article-title":"Thrombolysis in Myocardial Infarction (TIMI) Trial. Phase I. Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.","volume":"11","author":"Rao","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"R17-7-20210902","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"R18-7-20210902","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"R19-7-20210902","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/CIR.0b013e3181cd3d17","article-title":"Balancing benefit and bleeding risk of antithrombotic agents in the individual patient with an acute coronary syndrome.","volume":"121","author":"Van de Werf","year":"2010","journal-title":"Circulation"},{"key":"R20-7-20210902","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.109.878017","article-title":"Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy Trial.","volume":"121","author":"Pocock","year":"2010","journal-title":"Circulation"},{"key":"R21-7-20210902","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"R23-7-20210902","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","article-title":"Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable Angina to prevent Recurrent ischemic Events (CURE) Trial.","volume":"110","author":"Fox","year":"2004","journal-title":"Circulation"},{"key":"R24-7-20210902","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"key":"R25-7-20210902","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes.","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"R26-7-20210902","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes.","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"R27-7-20210902","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel.","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"R28-7-20210902","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jacc.2004.09.067","article-title":"Variability in platelet responsiveness to clopidogrel among 544 individuals.","volume":"45","author":"Serebruany","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R29-7-20210902","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"R30-7-20210902","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1111\/j.1538-7836.2006.02162.x","article-title":"Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin.","volume":"4","author":"Gilard","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R32-7-20210902","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/eurheartj\/ehi877","article-title":"Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.","volume":"27","author":"Jernberg","year":"2006","journal-title":"Eur Heart J"},{"key":"R33-7-20210902","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.amjcard.2007.11.057","article-title":"Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events.","volume":"101","author":"Bowry","year":"2008","journal-title":"Am J Cardiol"},{"key":"R34-7-20210902","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/ALN.0b013e3181870a4b","article-title":"Noncardiac surgery for patients with coronary artery stents: timing is everything.","volume":"109","author":"Rade","year":"2008","journal-title":"Anesthesiology"},{"key":"R35-7-20210902","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jama.297.2.joc60179","article-title":"Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.","volume":"297","author":"Eisenstein","year":"2007","journal-title":"JAMA"},{"key":"R36-7-20210902","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.athoracsur.2004.09.046","article-title":"In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution.","volume":"79","author":"Ascione","year":"2005","journal-title":"Ann Thorac Surg"},{"key":"R38-7-20210902","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0735-1097(02)01954-X","article-title":"The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting.","volume":"40","author":"Hongo","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R40-7-20210902","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/archinternmed.2009.42","article-title":"Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery.","volume":"169","author":"Blasco-Colmenares","year":"2009","journal-title":"Arch Intern Med"},{"key":"R41-7-20210902","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSETOFFSET study.","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"R42-7-20210902","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11239-007-0016-x","article-title":"Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28.","volume":"24","author":"McLean","year":"2007","journal-title":"J Thromb Thrombolysis"},{"key":"R43-7-20210902","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1161\/CIRCULATIONAHA.109.877944","article-title":"Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy.","volume":"121","author":"Goto","year":"2010","journal-title":"Circulation"},{"key":"R46-7-20210902","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","article-title":"Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.","volume":"295","author":"Kastrati","year":"2006","journal-title":"JAMA"},{"key":"R47-7-20210902","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","article-title":"Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study.","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"R48-7-20210902","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","article-title":"Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.","volume":"356","year":"2000","journal-title":"Lancet"},{"key":"R49-7-20210902","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"R50-7-20210902","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIbIIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.","volume":"338","year":"1998","journal-title":"N Engl J Med"},{"key":"R51-7-20210902","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIbIIIa with eptifibatide in patients with acute coronary syndromes.","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"R52-7-20210902","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1161\/01.CIR.90.4.1757","article-title":"Pharmacodynamics of chimeric glycoprotein IIbIIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.","volume":"90","author":"Tcheng","year":"1994","journal-title":"Circulation"},{"key":"R53-7-20210902","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIbIIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.","volume":"359","author":"Boersma","year":"2002","journal-title":"Lancet"},{"key":"R54-7-20210902","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1001\/jama.2009.1800","article-title":"Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention.","volume":"302","author":"Tsai","year":"2009","journal-title":"JAMA"},{"key":"R55-7-20210902","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0003-4975(00)01343-6","article-title":"Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIbIIIa blockade. Evaluation of Platelet IIbIIIa Inhibition in STENTing.","volume":"70","author":"Lincoff","year":"2000","journal-title":"Ann Thorac Surg"},{"key":"R56-7-20210902","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0003-4975(97)01299-X","article-title":"Abciximab and excessive bleeding in patients undergoing emergency cardiac operations.","volume":"65","author":"Gammie","year":"1998","journal-title":"Ann Thorac Surg"},{"key":"R57-7-20210902","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1067\/mtc.2001.117838","article-title":"Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting.","volume":"122","author":"Bizzarri","year":"2001","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R58-7-20210902","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0003-4975(00)01654-4","article-title":"Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIbIIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy.","volume":"70","author":"Dyke","year":"2000","journal-title":"Ann Thorac Surg"},{"key":"R59-7-20210902","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/j.jacc.2006.12.049","article-title":"The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial.","volume":"49","author":"Fox","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R60-7-20210902","doi-asserted-by":"crossref","first-page":"188S","DOI":"10.1378\/chest.126.3_suppl.188S","article-title":"Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.","volume":"126","author":"Hirsh","year":"2004","journal-title":"Chest"},{"key":"R61-7-20210902","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"R62-7-20210902","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1067\/mhj.2002.126115","article-title":"Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study.","volume":"144","author":"Cohen","year":"2002","journal-title":"Am Heart J"},{"key":"R63-7-20210902","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/01.CIR.0000050144.67910.13","article-title":"Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIbIIIa inhibitor eptifibatide.","volume":"107","author":"Goodman","year":"2003","journal-title":"Circulation"},{"key":"R66-7-20210902","first-page":"272","article-title":"Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.","volume":"13","author":"Kereiakes","year":"2001","journal-title":"J Invasive Cardiol"},{"key":"R67-7-20210902","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1056\/NEJMoa052711","article-title":"Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.","volume":"355","author":"Montalescot","year":"2006","journal-title":"N Engl J Med"},{"key":"R68-7-20210902","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jama.292.1.89","article-title":"Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview.","volume":"292","author":"Petersen","year":"2004","journal-title":"JAMA"},{"key":"R72-7-20210902","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ahj.2007.12.002","article-title":"Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict.","volume":"155","author":"Chew","year":"2008","journal-title":"Am Heart J"},{"key":"R73-7-20210902","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(02)07495-0","article-title":"Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients data.","volume":"359","year":"2002","journal-title":"Lancet"},{"key":"R74-7-20210902","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIbIIIa blockade compared with heparin and planned glycoprotein IIbIIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"R75-7-20210902","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jama.292.6.696","article-title":"Long-term efficacy of bivalirudin and provisional glycoprotein IIbIIIa blockade vs heparin and planned glycoprotein IIbIIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.","volume":"292","author":"Lincoff","year":"2004","journal-title":"JAMA"},{"key":"R76-7-20210902","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes.","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"R78-7-20210902","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","article-title":"Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators.","volume":"333","author":"Bittle","year":"1995","journal-title":"N Engl J Med"},{"key":"R79-7-20210902","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMoa0802944","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.","volume":"359","author":"Kastrati","year":"2008","journal-title":"N Engl J Med"},{"key":"R80-7-20210902","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1540-8183.2009.00494.x","article-title":"Outcomes of patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombotic therapy: pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.","volume":"22","author":"Doll","year":"2009","journal-title":"J Interv Cardiol"},{"key":"R81-7-20210902","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jtcvs.2005.10.049","article-title":"Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study.","volume":"131","author":"Smedira","year":"2006","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R82-7-20210902","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1213\/01.ane.0000226098.95698.0f","article-title":"Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the EVOLUTION OFF trial.","volume":"103","author":"Koster","year":"2006","journal-title":"Anesth Analg"},{"key":"R83-7-20210902","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.athoracsur.2006.09.038","article-title":"Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial.","volume":"83","author":"Koster","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"R84-7-20210902","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.athoracsur.2007.04.007","article-title":"Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor fourheparin antibodies.","volume":"84","author":"Dyke","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"R85-7-20210902","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.beha.2004.03.004","article-title":"Fondaparinux: a new synthetic and selective inhibitor of factor Xa.","volume":"17","author":"Bauer","year":"2004","journal-title":"Best Pract Res Clin Haematol"},{"key":"R86-7-20210902","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes.","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"R88-7-20210902","doi-asserted-by":"crossref","first-page":"S1814","DOI":"10.1016\/S0003-4975(01)03218-0","article-title":"Pharmacologic preservation of the hemostatic system during cardiac surgery.","volume":"72","author":"Levy","year":"2001","journal-title":"Ann Thorac Surg"},{"key":"R89-7-20210902","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/archsurg.144.1.69","article-title":"Antiplatelet agents in the perioperative period.","volume":"144","author":"ORiordan","year":"2009","journal-title":"Arch Surg"},{"key":"R90-7-20210902","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1538-7836.2006.02245.x","article-title":"Normalization of platelet reactivity in clopidogrel-treated subjects.","volume":"5","author":"Vilahur","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R91-7-20210902","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1213\/ane.0b013e31819bcc9c","article-title":"Blood coagulation: hemostasis and thrombin regulation.","volume":"108","author":"Tanaka","year":"2009","journal-title":"Anesth Analg"},{"key":"R95-7-20210902","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.108.834275","article-title":"Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery.","volume":"120","author":"Gill","year":"2009","journal-title":"Circulation"},{"key":"R96-7-20210902","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1097\/00001721-200405001-00007","article-title":"Recombinant activated factor VII in cardiac surgery.","volume":"15","author":"Herbertson","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R97-7-20210902","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1445-5994.2007.01472.x","article-title":"Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register.","volume":"38","author":"Isbister","year":"2008","journal-title":"Intern Med J"},{"key":"R98-7-20210902","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/BF03022836","article-title":"Audit of factor VIIa for bleeding resistant to conventional therapy following complex cardiac surgery.","volume":"53","author":"McCall","year":"2006","journal-title":"Can J Anaesth"},{"key":"R99-7-20210902","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1097\/01.CCM.0000181527.47749.57","article-title":"Recombinant activated factor VII for refractory bleeding after cardiac surgery: a retrospective analysis of safety and efficacy.","volume":"33","author":"von Heymann","year":"2005","journal-title":"Crit Care Med"},{"key":"R100-7-20210902","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/BF03022797","article-title":"Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery.","volume":"53","author":"Karkouti","year":"2006","journal-title":"Can J Anaesth"},{"key":"R101-7-20210902","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1067\/mhj.2001.115295","article-title":"The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2.","volume":"141","author":"Barron","year":"2001","journal-title":"Am Heart J"},{"key":"R102-7-20210902","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11897-008-0025-x","article-title":"Percutaneous ventricular assist devices for cardiogenic shock.","volume":"5","author":"Cook","year":"2008","journal-title":"Curr Heart Fail Rep"},{"key":"R103-7-20210902","first-page":"1123","article-title":"Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry.","volume":"36","author":"Sanborn","year":"2000","journal-title":"SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK J Am Coll Cardiol"},{"key":"R104-7-20210902","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0735-1097(97)00088-0","article-title":"A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. Second Primary Angioplasty in Myocardial Infarction (PAMI-II) Trial Investigators.","volume":"29","author":"Stone","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"R105-7-20210902","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1053\/euhj.1998.1348","article-title":"A randomized comparison of intra-aortic balloon pumping after primary coronary angioplasty in high risk patients with acute myocardial infarction.","volume":"20","author":"vant Hof","year":"1999","journal-title":"Eur Heart J"},{"key":"R106-7-20210902","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJM197203232861204","article-title":"Prolonged extracorporeal oxygenation for acute post-traumatic respiratory failure (shock-lung syndrome): use of the Bramson membrane lung.","volume":"286","author":"Hill","year":"1972","journal-title":"N Engl J Med"},{"key":"R107-7-20210902","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1001\/jama.1979.03300200023016","article-title":"Extracorporeal membrane oxygenation in severe acute respiratory failure: a randomized prospective study.","volume":"242","author":"Zapol","year":"1979","journal-title":"JAMA"},{"key":"R108-7-20210902","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1053\/j.jvca.2009.08.006","article-title":"Extracorporeal membrane oxygenation for treating severe cardiac and respiratory disease in adults: Part 1. Overview of extracorporeal membrane oxygenation.","volume":"23","author":"Sidebotham","year":"2009","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R109-7-20210902","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/MAT.0b013e3181a44263","article-title":"Performance of a MedArray silicone hollow fiber oxygenator.","volume":"55","author":"LaFayette","year":"2009","journal-title":"ASAIO J"},{"key":"R110-7-20210902","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00002216-198907000-00154","article-title":"Technical aspects of plasma leakage prevention in microporous capillary membrane oxygenators.","volume":"38","author":"Mottaghy","year":"1989","journal-title":"ASAIO J"},{"key":"R111-7-20210902","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/00002480-200209000-00007","article-title":"Early experience with a polymethyl pentene oxygenator for adult extracorporeal life support.","volume":"48","author":"Peek","year":"2002","journal-title":"ASAIO J"},{"key":"R112-7-20210902","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/01.mat.0000169111.66328.a8","article-title":"A polymethylpentene fiber gas exchanger for long-term extracorporeal life support.","volume":"51","author":"Toomasian","year":"2005","journal-title":"ASAIO J"},{"key":"R113-7-20210902","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MAT.0b013e31815ff27e","article-title":"Extracorporeal membrane oxygenation with a poly-methylpentene oxygenator (Quadrox D): the experience of a single Italian centre in adult patients with refractory cardiogenic shock.","volume":"54","author":"Formica","year":"2008","journal-title":"ASAIO J"},{"key":"R114-7-20210902","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/MAT.0b013e3181bad907","article-title":"Use of extracorporeal membrane oxygenation for adults in cardiac arrest (E-CPR): a meta-analysis of observational studies.","volume":"55","author":"Cardarelli","year":"2009","journal-title":"ASAIO J"},{"key":"R115-7-20210902","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jacc.2008.05.065","article-title":"A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction.","volume":"52","author":"Seyfarth","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R116-7-20210902","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.athoracsur.2008.12.079","article-title":"Extracorporeal membrane oxygenation to support cardiopulmonary resuscitation in adults.","volume":"87","author":"Thiagarajan","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"R117-7-20210902","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0300-9572(03)00215-6","article-title":"Cardiopulmonary resuscitation of adults in the hospital: a report of 14720 cardiac arrests from the National Registry of Cardiopulmonary Resuscitation.","volume":"58","author":"Peberdy","year":"2003","journal-title":"Resuscitation"},{"key":"R118-7-20210902","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.healun.2005.10.011","article-title":"Improved survival after acute myocardial infarction complicated by cardiogenic shock with circulatory support and transplantation: comparing aggressive intervention with conservative treatment.","volume":"25","author":"Tayara","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"R119-7-20210902","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1161\/hc4901.100361","article-title":"Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance.","volume":"104","author":"Thiele","year":"2001","journal-title":"Circulation"},{"key":"R120-7-20210902","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ccd.20796","article-title":"Feasibility study of the use of the TandemHeart percutaneous ventricular assist device for treatment of cardiogenic shock.","volume":"68","author":"Burkhoff","year":"2006","journal-title":"Catheter Cardiovasc Interv"},{"key":"R121-7-20210902","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.athoracsur.2007.06.048","article-title":"Feasibility study of a temporary percutaneous left ventricular assist device in cardiac surgery.","volume":"84","author":"Pitsis","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"R122-7-20210902","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.athoracsur.2009.07.015","article-title":"Role of a percutaneous ventricular assist device in decision making for a cardiac transplant program.","volume":"88","author":"Brinkman","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"R124-7-20210902","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/eurheartj\/ehi161","article-title":"Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock.","volume":"26","author":"Thiele","year":"2005","journal-title":"Eur Heart J"},{"key":"R125-7-20210902","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2005.10.037","article-title":"Safety and feasibility of elective high-risk percutaneous coronary intervention procedures with left ventricular support of the Impella Recover LP 2.5.","volume":"97","author":"Henriques","year":"2006","journal-title":"Am J Cardiol"},{"key":"R126-7-20210902","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.hlc.2008.02.003","article-title":"Left ventricular support with the Impella LP 5.0 for cardiogenic shock following cardiac surgery.","volume":"17","author":"Rossiter-Thornton","year":"2008","journal-title":"Heart Lung Circ"},{"key":"R127-7-20210902","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1525-1594.2006.00254.x","article-title":"Left ventricular mechanical support with the Impella Recover left direct microaxial blood pump: a single-center experience.","volume":"30","author":"Garatti","year":"2006","journal-title":"Artif Organs"},{"key":"R128-7-20210902","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1510\/icvts.2008.199208","article-title":"The Impella LP 5.0 as a bridge to long-term circulatory support.","volume":"8","author":"Samoukovic","year":"2009","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"R129-7-20210902","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/MCC.0b013e3282efd5bc","article-title":"Percutaneous left ventricular assist devices for treatment of patients with cardiogenic shock.","volume":"13","author":"Windecker","year":"2007","journal-title":"Curr Opin Crit Care"},{"key":"R130-7-20210902","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ccd.20380","article-title":"Left ventricular unloading and concomitant total cardiac output increase by the use of percutaneous Impella Recover LP 2.5 assist device during high-risk coronary intervention.","volume":"65","author":"Valgimigli","year":"2005","journal-title":"Catheter Cardiovasc Interv"},{"key":"R131-7-20210902","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1213\/01.ane.0000243330.74987.28","article-title":"Placement of the TandemHeart percutaneous left ventricular assist device.","volume":"103","author":"Pretorius","year":"2006","journal-title":"Anesth Analg"},{"key":"R132-7-20210902","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00134-005-0016-2","article-title":"Ventricular unloading with a miniature axial flow pump in combination with extracorporeal membrane oxygenation.","volume":"32","author":"Vlasselaers","year":"2006","journal-title":"Intensive Care Med"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0b013e31820e7e4f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:25:16Z","timestamp":1786112716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000539-201104000-00007"}},"subtitle":["A Review of the Evidence and Perioperative Implications of Medical and Mechanical Therapeutics"],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0b013e31820e7e4f","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}